FindTrial
Sign In

Efficacy and safety of polymyxin B intravenous combined with nebulization in the treatment of MDR pneumonia

Efficacy and safety of polymyxin B intravenous combined with nebulization in the treatment of MDR pneumonia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300067419
Enrollment
Unknown
Registered
2023-01-06
Start date
2023-02-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe MDR pneumonia

Interventions

Intravenous + nebulization:Intravenous + nebulization
Intravenous :Intravenous

Sponsors

HEBEI GENERAL HOSPITAL
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. age >18 years; 2. severe pneumonia + mechanical ventilation diagnostic criteria HAP VAP; 3. pneumonia diagnosed on chest imaging and confirmed to be caused by G-multi-drug resistant bacteria; 4. impaired oxygenation (P/F =300 mmHg) within 48 hours prior to enrollment; 5. modified clinical pulmonary infection score (CPIS) =6

Exclusion criteria

Exclusion criteria: History of bronchial asthma, history of allergy to mucin B sulfate, intolerance to nebulized mucin B, pregnancy, lactation, intravenous antibiotics for G-bacterial pneumonia >48h before enrollment, except for antibiotic resistance or exacerbation of pneumonia, lung cancer with obstructive pneumonia, mucin-resistant gram-negative bacilli

Design outcomes

Primary

MeasureTime frame
Clinical cure rate;—

Secondary

MeasureTime frame
all cause mortality;—

Countries

China

Contacts

Public ContactZhao Heling

Hebei General Hospital

zhheling@sina.com13831129968

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026